Yes, the circumstances may have changed somewhat with the recent failure of competitors. After chatting with an expert in the field it seems there is a growing belief that OPT302 is the most likely successful candidate to improve outcomes in combination with VEGFA inhibitors.
My view is that the recent sell down has created an opportunity for investors. Novartis was willing to pay USD1 billion for a combination therapy. Maybe the stakes are even higher now, and maybe licensing combination therapies with multiple companies products would provide an even better return.
- Forums
- ASX - By Stock
- OPT
- Ann: Trading Halt
Ann: Trading Halt, page-13
Featured News
Add OPT (ASX) to my watchlist
(20min delay)
|
|||||
Last
83.5¢ |
Change
-0.005(0.60%) |
Mkt cap ! $1.027B |
Open | High | Low | Value | Volume |
85.5¢ | 85.5¢ | 82.0¢ | $11.20M | 13.42M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 13018 | 83.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
84.0¢ | 3897 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 13018 | 0.830 |
2 | 14230 | 0.825 |
3 | 17895 | 0.820 |
4 | 31905 | 0.815 |
3 | 14224 | 0.810 |
Price($) | Vol. | No. |
---|---|---|
0.840 | 3897 | 1 |
0.850 | 9739 | 1 |
0.855 | 20950 | 3 |
0.860 | 13018 | 1 |
0.865 | 83653 | 6 |
Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
Harsh Shethia, Advisor
Harsh Shethia
Advisor
SPONSORED BY The Market Online